Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging

被引：0
|
作者：
Dijkers, E.
Lub-de Hooge, M. N.
Kosterink, J. G.
Jager, P. L.
Brouwers, A. H.
Perk, L. R.
van Dongen, G. A.
de Vries, E. G.
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
    Dijkers, Eli C. F.
    Kosterink, Jos G. W.
    Rademaker, Anna P.
    Perk, Lars R.
    van Dongen, Guus A. M. S.
    Bart, Joost
    de Jong, Johan R.
    de Vries, Elisabeth G. E.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) : 974 - 981
  • [2] 89Zr-trastuzumab immunoPET imaging to monitor src status after treatment in HER2 breast cancer
    McKnight, Brooke N.
    Viola-Villegas, Nerissa T.
    CANCER RESEARCH, 2017, 77
  • [3] Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo
    Janjigian, Y. Y.
    Villegas, N. T.
    Holland, J. P.
    Shah, M. A.
    Divilov, V.
    Kelsen, D. P.
    Lewis, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] HER-2-PET imaging with 89Zr-trastuzumab in metastatic breast cancer patients
    Munnink, T. Oude
    Dijkers, E.
    Hooge, M. Lub-de
    Kosterink, J.
    Brouwers, A.
    de Jong, J.
    van Dongen, G.
    de Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Mucolytic drug N-Acetylcystein improves 89Zr-trastuzumab HER2-immunoPET imaging by restoring accessibility to HER2 hampered by membrane mucin overexpression in a HER2 positive MUC4 overexpressing xenograft mouse model
    Wimana, Zena
    Gebhart, Geraldine
    Morandini, Renato
    Flamen, Patrick
    Ghanem, Ghanem
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Clinical value of 89Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
    Schroder, C. P.
    Bensch, F.
    Brouwers, A. H.
    Lub-de Hooge, M. N.
    de Jong, J. R.
    van der Vegt, B.
    Sleijfer, S.
    de Vries, E. G.
    CANCER RESEARCH, 2017, 77
  • [7] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [8] 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
    Bensch, Frederike
    Brouwers, A. H.
    Lub-de Hooge, M. N.
    de Jong, J. R.
    van der Vegt, B.
    Sleijfer, S.
    de Vries, E. G. E.
    Schroeder, C. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (13) : 2300 - 2306
  • [9] Interference of mucin in the binding of 89Zr-trastuzumab on HER2 receptor and influence of mucolytic agents in the HER2 positive MUC4 overexpressing trastuzumab resistant JIMT1 cell line
    Wimana, Zena
    Gebhart, Geraldine
    Morandini, Renato
    Flamen, Patrick
    Ghanem, Ghanem-Elias
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging
    Brooke N. McKnight
    Nerissa T. Viola-Villegas
    Breast Cancer Research, 20
12345